Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatoblastoma | 19 | 2024 | 180 | 8.160 |
Why?
|
Liver Neoplasms | 29 | 2024 | 1316 | 5.870 |
Why?
|
Neuroblastoma | 24 | 2021 | 529 | 2.570 |
Why?
|
Carcinoma, Hepatocellular | 11 | 2024 | 933 | 1.620 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 6 | 2024 | 93 | 1.310 |
Why?
|
Sarcoma | 6 | 2024 | 184 | 1.150 |
Why?
|
Pancreatic Neoplasms | 4 | 2022 | 690 | 1.120 |
Why?
|
Margins of Excision | 2 | 2024 | 51 | 1.110 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2024 | 74 | 0.980 |
Why?
|
Sarcoma, Synovial | 1 | 2024 | 21 | 0.910 |
Why?
|
Child | 57 | 2025 | 24575 | 0.900 |
Why?
|
Pancreaticoduodenectomy | 3 | 2022 | 91 | 0.860 |
Why?
|
Neuroendocrine Tumors | 3 | 2021 | 54 | 0.860 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2024 | 1153 | 0.830 |
Why?
|
Infant | 32 | 2025 | 12581 | 0.770 |
Why?
|
Hemangiosarcoma | 1 | 2022 | 41 | 0.750 |
Why?
|
Prognosis | 18 | 2024 | 4677 | 0.750 |
Why?
|
Humans | 103 | 2025 | 125331 | 0.750 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2021 | 10 | 0.740 |
Why?
|
Hepatectomy | 4 | 2023 | 112 | 0.720 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2021 | 21 | 0.720 |
Why?
|
Peritonitis | 1 | 2021 | 74 | 0.720 |
Why?
|
Cytoreduction Surgical Procedures | 1 | 2021 | 43 | 0.710 |
Why?
|
Peritoneal Neoplasms | 1 | 2021 | 42 | 0.700 |
Why?
|
Metastasectomy | 2 | 2020 | 10 | 0.670 |
Why?
|
Exocrine Pancreatic Insufficiency | 1 | 2020 | 35 | 0.670 |
Why?
|
Adolescent | 37 | 2025 | 19419 | 0.660 |
Why?
|
Child, Preschool | 33 | 2025 | 14123 | 0.660 |
Why?
|
Retrospective Studies | 35 | 2024 | 16344 | 0.650 |
Why?
|
Cell Line, Tumor | 22 | 2024 | 3415 | 0.650 |
Why?
|
Doxorubicin | 11 | 2024 | 288 | 0.640 |
Why?
|
Lung Neoplasms | 6 | 2021 | 1654 | 0.620 |
Why?
|
Pneumonectomy | 2 | 2021 | 143 | 0.610 |
Why?
|
Tumor Suppressor Protein p53 | 7 | 2021 | 746 | 0.570 |
Why?
|
Liver Transplantation | 3 | 2023 | 1042 | 0.560 |
Why?
|
Databases, Factual | 8 | 2019 | 1174 | 0.540 |
Why?
|
Indocyanine Green | 3 | 2024 | 54 | 0.530 |
Why?
|
Up-Regulation | 2 | 2021 | 875 | 0.530 |
Why?
|
Treatment Outcome | 18 | 2023 | 12290 | 0.520 |
Why?
|
Female | 61 | 2025 | 66836 | 0.520 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 376 | 0.490 |
Why?
|
Postoperative Complications | 7 | 2021 | 3055 | 0.490 |
Why?
|
Liver | 3 | 2024 | 1748 | 0.490 |
Why?
|
Dipeptides | 2 | 2016 | 57 | 0.490 |
Why?
|
Adenoma, Liver Cell | 1 | 2015 | 4 | 0.480 |
Why?
|
Hernia, Abdominal | 1 | 2015 | 18 | 0.480 |
Why?
|
Kidney Neoplasms | 4 | 2025 | 440 | 0.470 |
Why?
|
Cell Proliferation | 12 | 2019 | 2371 | 0.470 |
Why?
|
Duodenal Diseases | 1 | 2015 | 34 | 0.470 |
Why?
|
Male | 51 | 2025 | 61573 | 0.460 |
Why?
|
Wilms Tumor | 3 | 2025 | 117 | 0.460 |
Why?
|
Focal Nodular Hyperplasia | 1 | 2014 | 6 | 0.460 |
Why?
|
Intestinal Volvulus | 1 | 2015 | 38 | 0.460 |
Why?
|
N-Myc Proto-Oncogene Protein | 4 | 2021 | 64 | 0.450 |
Why?
|
Survival Rate | 12 | 2025 | 2046 | 0.420 |
Why?
|
Follow-Up Studies | 14 | 2024 | 5166 | 0.420 |
Why?
|
Xenograft Model Antitumor Assays | 14 | 2024 | 914 | 0.420 |
Why?
|
Chronic Pain | 1 | 2015 | 126 | 0.410 |
Why?
|
Apoptosis | 12 | 2021 | 1816 | 0.400 |
Why?
|
Neoplasm Proteins | 3 | 2019 | 681 | 0.400 |
Why?
|
Combined Modality Therapy | 8 | 2024 | 1236 | 0.400 |
Why?
|
Abdominal Pain | 1 | 2015 | 307 | 0.400 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 280 | 0.390 |
Why?
|
Analgesia, Epidural | 2 | 2022 | 29 | 0.370 |
Why?
|
Electricity | 1 | 2011 | 9 | 0.370 |
Why?
|
Hemangioma | 2 | 2018 | 94 | 0.370 |
Why?
|
Crystallization | 1 | 2011 | 83 | 0.360 |
Why?
|
Neoplasm Staging | 10 | 2022 | 1275 | 0.360 |
Why?
|
Alanine | 1 | 2011 | 187 | 0.350 |
Why?
|
Lasers | 1 | 2011 | 114 | 0.350 |
Why?
|
Infant, Newborn | 18 | 2025 | 8259 | 0.350 |
Why?
|
Soft Tissue Neoplasms | 3 | 2019 | 122 | 0.350 |
Why?
|
Gene Expression Regulation, Neoplastic | 9 | 2021 | 1980 | 0.340 |
Why?
|
Thoracic Neoplasms | 3 | 2021 | 37 | 0.320 |
Why?
|
Protein Kinase Inhibitors | 4 | 2019 | 543 | 0.320 |
Why?
|
Mice | 19 | 2024 | 17736 | 0.320 |
Why?
|
Survival Analysis | 9 | 2021 | 1493 | 0.320 |
Why?
|
Pancreatectomy | 3 | 2022 | 137 | 0.310 |
Why?
|
Optical Imaging | 2 | 2021 | 66 | 0.310 |
Why?
|
Osteosarcoma | 3 | 2021 | 255 | 0.300 |
Why?
|
Surgical Oncology | 3 | 2024 | 12 | 0.300 |
Why?
|
Healthcare Disparities | 3 | 2017 | 436 | 0.300 |
Why?
|
Animals | 24 | 2024 | 34298 | 0.280 |
Why?
|
Cell Survival | 6 | 2021 | 819 | 0.280 |
Why?
|
Reoperation | 2 | 2024 | 829 | 0.280 |
Why?
|
Biopsy | 3 | 2018 | 1241 | 0.270 |
Why?
|
Mice, Nude | 9 | 2021 | 725 | 0.270 |
Why?
|
Quinazolines | 2 | 2019 | 175 | 0.270 |
Why?
|
Mitogen-Activated Protein Kinase Phosphatases | 3 | 2015 | 15 | 0.270 |
Why?
|
Rectal Neoplasms | 2 | 2020 | 78 | 0.270 |
Why?
|
Dual-Specificity Phosphatases | 3 | 2015 | 22 | 0.270 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 2 | 2015 | 126 | 0.260 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2019 | 61 | 0.260 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2006 | 42 | 0.250 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2006 | 30 | 0.250 |
Why?
|
Carcinoma | 4 | 2016 | 290 | 0.240 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2022 | 366 | 0.240 |
Why?
|
Thyroidectomy | 2 | 2017 | 100 | 0.240 |
Why?
|
Vincristine | 2 | 2024 | 191 | 0.240 |
Why?
|
Quinolines | 2 | 2017 | 103 | 0.240 |
Why?
|
Gene Knockdown Techniques | 4 | 2021 | 367 | 0.240 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2017 | 436 | 0.240 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2005 | 79 | 0.240 |
Why?
|
Bone Neoplasms | 2 | 2020 | 427 | 0.240 |
Why?
|
Rhabdomyosarcoma | 2 | 2017 | 191 | 0.230 |
Why?
|
Membrane Proteins | 2 | 2009 | 1537 | 0.230 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 2 | 2019 | 145 | 0.230 |
Why?
|
Etoposide | 4 | 2019 | 114 | 0.220 |
Why?
|
Adult | 17 | 2024 | 29607 | 0.220 |
Why?
|
Hydroxamic Acids | 1 | 2024 | 56 | 0.220 |
Why?
|
Thoracoscopy | 2 | 2021 | 43 | 0.220 |
Why?
|
Thyroid Neoplasms | 2 | 2017 | 189 | 0.220 |
Why?
|
Ovarian Neoplasms | 2 | 2017 | 420 | 0.210 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2024 | 77 | 0.210 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1242 | 0.210 |
Why?
|
Disease-Free Survival | 7 | 2020 | 880 | 0.210 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 3603 | 0.200 |
Why?
|
Dependovirus | 1 | 2024 | 128 | 0.200 |
Why?
|
Neoplasm Invasiveness | 4 | 2017 | 625 | 0.200 |
Why?
|
Adenocarcinoma | 2 | 2020 | 1025 | 0.190 |
Why?
|
Esophageal Stenosis | 1 | 2002 | 46 | 0.190 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 58 | 0.190 |
Why?
|
Heart Defects, Congenital | 3 | 2024 | 1830 | 0.190 |
Why?
|
Yttrium Radioisotopes | 1 | 2021 | 19 | 0.190 |
Why?
|
Recurrence | 2 | 2023 | 1391 | 0.190 |
Why?
|
Enzyme Inhibitors | 2 | 2015 | 587 | 0.190 |
Why?
|
Young Adult | 13 | 2025 | 9066 | 0.190 |
Why?
|
Hep G2 Cells | 2 | 2018 | 85 | 0.190 |
Why?
|
Chromatin Assembly Factor-1 | 1 | 2021 | 9 | 0.190 |
Why?
|
Ganglioneuroblastoma | 1 | 2021 | 6 | 0.190 |
Why?
|
Antineoplastic Agents | 6 | 2021 | 1711 | 0.190 |
Why?
|
Ganglioneuroma | 1 | 2021 | 17 | 0.190 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2021 | 18 | 0.190 |
Why?
|
Cyanosis | 1 | 2001 | 42 | 0.180 |
Why?
|
Proportional Hazards Models | 7 | 2021 | 1358 | 0.180 |
Why?
|
Oxadiazoles | 1 | 2021 | 25 | 0.180 |
Why?
|
Pancreas | 1 | 2022 | 220 | 0.180 |
Why?
|
Monitoring, Intraoperative | 1 | 2001 | 133 | 0.180 |
Why?
|
Heterografts | 5 | 2024 | 175 | 0.170 |
Why?
|
Carbon Dioxide | 1 | 2001 | 279 | 0.170 |
Why?
|
Neoplasm Transplantation | 2 | 2017 | 383 | 0.170 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 62 | 0.160 |
Why?
|
Drug Synergism | 5 | 2019 | 227 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 2 | 2017 | 80 | 0.160 |
Why?
|
Nephrectomy | 2 | 2018 | 178 | 0.160 |
Why?
|
Thoracotomy | 1 | 2020 | 109 | 0.160 |
Why?
|
Piperidones | 1 | 2019 | 7 | 0.160 |
Why?
|
Thoracic Wall | 2 | 2019 | 38 | 0.160 |
Why?
|
Embolization, Therapeutic | 1 | 2021 | 216 | 0.160 |
Why?
|
Signal Transduction | 9 | 2021 | 4591 | 0.160 |
Why?
|
Piperazines | 1 | 2021 | 242 | 0.160 |
Why?
|
Phenylurea Compounds | 1 | 2019 | 49 | 0.150 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2019 | 733 | 0.150 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2019 | 51 | 0.150 |
Why?
|
Risk Assessment | 6 | 2020 | 3439 | 0.150 |
Why?
|
Cyclin D1 | 1 | 2018 | 113 | 0.150 |
Why?
|
Carcinogenesis | 1 | 2021 | 340 | 0.150 |
Why?
|
Gene Dosage | 1 | 2020 | 444 | 0.150 |
Why?
|
Dysgerminoma | 1 | 2017 | 5 | 0.150 |
Why?
|
Liver Neoplasms, Experimental | 1 | 2017 | 59 | 0.140 |
Why?
|
Age Factors | 6 | 2019 | 2824 | 0.140 |
Why?
|
Ascites | 1 | 2018 | 88 | 0.140 |
Why?
|
Consensus | 1 | 2021 | 644 | 0.140 |
Why?
|
Surgical Procedures, Operative | 2 | 2016 | 184 | 0.140 |
Why?
|
Proto-Oncogene Proteins | 1 | 2021 | 559 | 0.140 |
Why?
|
MAP Kinase Signaling System | 1 | 2019 | 314 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2018 | 208 | 0.140 |
Why?
|
United States | 11 | 2025 | 10922 | 0.140 |
Why?
|
Diagnosis, Differential | 3 | 2014 | 1898 | 0.140 |
Why?
|
Disease Models, Animal | 3 | 2024 | 4405 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-abl | 1 | 2017 | 12 | 0.140 |
Why?
|
Fertility Preservation | 1 | 2017 | 53 | 0.140 |
Why?
|
Aniline Compounds | 1 | 2017 | 19 | 0.140 |
Why?
|
Checkpoint Kinase 2 | 1 | 2016 | 36 | 0.130 |
Why?
|
Phantoms, Imaging | 1 | 2017 | 134 | 0.130 |
Why?
|
Carcinoma, Lobular | 1 | 2017 | 24 | 0.130 |
Why?
|
Sacroiliac Joint | 1 | 2016 | 5 | 0.130 |
Why?
|
Biomarkers, Tumor | 3 | 2024 | 1534 | 0.130 |
Why?
|
Neurofibrosarcoma | 1 | 2016 | 5 | 0.130 |
Why?
|
Sacrum | 1 | 2016 | 30 | 0.130 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 662 | 0.130 |
Why?
|
Hospitals, Low-Volume | 1 | 2016 | 30 | 0.130 |
Why?
|
Spinal Nerve Roots | 1 | 2016 | 26 | 0.130 |
Why?
|
Pelvic Bones | 1 | 2016 | 27 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 5 | 2017 | 1065 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 2089 | 0.130 |
Why?
|
Hospitals, High-Volume | 1 | 2016 | 35 | 0.130 |
Why?
|
Neovascularization, Pathologic | 1 | 2017 | 239 | 0.130 |
Why?
|
Testicular Neoplasms | 1 | 2017 | 133 | 0.130 |
Why?
|
Aminopyridines | 1 | 2016 | 56 | 0.130 |
Why?
|
Ultrasonography | 2 | 2015 | 939 | 0.130 |
Why?
|
src-Family Kinases | 1 | 2017 | 91 | 0.130 |
Why?
|
Epidermal Growth Factor | 1 | 2017 | 123 | 0.130 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2017 | 85 | 0.130 |
Why?
|
Nitriles | 1 | 2017 | 146 | 0.130 |
Why?
|
Insurance Coverage | 1 | 2017 | 120 | 0.130 |
Why?
|
Gene Amplification | 2 | 2014 | 236 | 0.130 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2015 | 11 | 0.130 |
Why?
|
Laparoscopy | 1 | 2001 | 490 | 0.130 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2016 | 57 | 0.120 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2015 | 37 | 0.120 |
Why?
|
Tumor Burden | 4 | 2019 | 231 | 0.120 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2016 | 101 | 0.120 |
Why?
|
Multidetector Computed Tomography | 1 | 2015 | 34 | 0.120 |
Why?
|
Benzoxazoles | 1 | 2015 | 11 | 0.120 |
Why?
|
Carcinoid Tumor | 1 | 2015 | 26 | 0.120 |
Why?
|
Appendiceal Neoplasms | 1 | 2015 | 18 | 0.120 |
Why?
|
Parathyroid Neoplasms | 1 | 2014 | 22 | 0.120 |
Why?
|
Intraoperative Care | 1 | 2015 | 105 | 0.120 |
Why?
|
Necrosis | 1 | 2015 | 209 | 0.110 |
Why?
|
Parathyroidectomy | 1 | 2014 | 49 | 0.110 |
Why?
|
Carcinoma, Renal Cell | 1 | 2016 | 240 | 0.110 |
Why?
|
MAP Kinase Kinase Kinase 3 | 1 | 2014 | 9 | 0.110 |
Why?
|
Zearalenone | 1 | 2013 | 4 | 0.110 |
Why?
|
Ubiquitin-Conjugating Enzymes | 1 | 2014 | 38 | 0.110 |
Why?
|
Cell Differentiation | 1 | 2021 | 1907 | 0.110 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 88 | 0.110 |
Why?
|
Gastrostomy | 1 | 2014 | 86 | 0.110 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 472 | 0.110 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2013 | 45 | 0.110 |
Why?
|
Multiprotein Complexes | 1 | 2015 | 210 | 0.110 |
Why?
|
Delayed Diagnosis | 1 | 2015 | 126 | 0.110 |
Why?
|
Lipoblastoma | 1 | 2013 | 6 | 0.110 |
Why?
|
alpha-Fetoproteins | 1 | 2014 | 131 | 0.100 |
Why?
|
Health Resources | 1 | 2014 | 116 | 0.100 |
Why?
|
Adenoma | 1 | 2014 | 128 | 0.100 |
Why?
|
Thiophenes | 1 | 2013 | 69 | 0.100 |
Why?
|
Breast Neoplasms | 2 | 2017 | 2518 | 0.100 |
Why?
|
Protease Inhibitors | 1 | 2013 | 96 | 0.100 |
Why?
|
Electrodes, Implanted | 1 | 2014 | 168 | 0.100 |
Why?
|
Colonic Neoplasms | 1 | 2015 | 248 | 0.100 |
Why?
|
Base Sequence | 2 | 2009 | 3108 | 0.100 |
Why?
|
Stomach Neoplasms | 1 | 2019 | 547 | 0.100 |
Why?
|
Catheterization, Central Venous | 1 | 2014 | 128 | 0.100 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 705 | 0.100 |
Why?
|
Intestinal Perforation | 1 | 2013 | 56 | 0.100 |
Why?
|
Cohort Studies | 6 | 2021 | 4837 | 0.100 |
Why?
|
Phosphorylation | 3 | 2014 | 1637 | 0.100 |
Why?
|
Abdominal Neoplasms | 1 | 2012 | 33 | 0.100 |
Why?
|
Molecular Sequence Data | 2 | 2009 | 3894 | 0.100 |
Why?
|
Head and Neck Neoplasms | 1 | 2017 | 503 | 0.100 |
Why?
|
Pyrimidines | 1 | 2015 | 377 | 0.090 |
Why?
|
Thermogravimetry | 1 | 2011 | 5 | 0.090 |
Why?
|
Transfection | 2 | 2014 | 1076 | 0.090 |
Why?
|
Spectroscopy, Fourier Transform Infrared | 1 | 2011 | 30 | 0.090 |
Why?
|
Spectrophotometry, Ultraviolet | 1 | 2011 | 45 | 0.090 |
Why?
|
Burkitt Lymphoma | 1 | 2013 | 143 | 0.090 |
Why?
|
Vibration | 1 | 2011 | 32 | 0.090 |
Why?
|
Fundoplication | 2 | 2002 | 69 | 0.090 |
Why?
|
Neurons | 1 | 2021 | 1941 | 0.090 |
Why?
|
Salivation | 1 | 2011 | 6 | 0.090 |
Why?
|
X-Ray Diffraction | 1 | 2011 | 96 | 0.090 |
Why?
|
Esophagoplasty | 1 | 2011 | 12 | 0.090 |
Why?
|
Glycopyrrolate | 1 | 2011 | 9 | 0.090 |
Why?
|
Chest Tubes | 1 | 2011 | 35 | 0.090 |
Why?
|
Mutation | 3 | 2022 | 5900 | 0.090 |
Why?
|
Intestines | 1 | 2015 | 577 | 0.090 |
Why?
|
Diagnostic Errors | 1 | 2015 | 334 | 0.090 |
Why?
|
Operative Time | 2 | 2021 | 165 | 0.090 |
Why?
|
Anastomotic Leak | 1 | 2011 | 31 | 0.090 |
Why?
|
Muscarinic Antagonists | 1 | 2011 | 37 | 0.090 |
Why?
|
Incidence | 4 | 2025 | 3134 | 0.090 |
Why?
|
Esophageal Atresia | 1 | 2011 | 51 | 0.090 |
Why?
|
Tracheoesophageal Fistula | 1 | 2011 | 48 | 0.090 |
Why?
|
Analgesics | 2 | 2022 | 127 | 0.090 |
Why?
|
Age Distribution | 3 | 2016 | 417 | 0.080 |
Why?
|
Crystallography, X-Ray | 1 | 2011 | 357 | 0.080 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2011 | 295 | 0.080 |
Why?
|
SEER Program | 2 | 2025 | 202 | 0.080 |
Why?
|
Melanoma | 1 | 2017 | 943 | 0.080 |
Why?
|
Skin Neoplasms | 1 | 2017 | 860 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 92 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 108 | 0.080 |
Why?
|
Predictive Value of Tests | 2 | 2007 | 2175 | 0.080 |
Why?
|
Computational Biology | 2 | 2014 | 819 | 0.080 |
Why?
|
Pain, Postoperative | 2 | 2022 | 259 | 0.080 |
Why?
|
Quality Improvement | 1 | 2014 | 646 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2019 | 1691 | 0.070 |
Why?
|
Infant, Premature | 2 | 2019 | 830 | 0.070 |
Why?
|
Severity of Illness Index | 2 | 2006 | 2906 | 0.070 |
Why?
|
Analgesics, Opioid | 2 | 2022 | 408 | 0.070 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2019 | 128 | 0.060 |
Why?
|
Neoplasm, Residual | 1 | 2007 | 121 | 0.060 |
Why?
|
Esophagus | 2 | 2011 | 223 | 0.060 |
Why?
|
Biopsy, Needle | 2 | 2020 | 228 | 0.060 |
Why?
|
Brain Neoplasms | 1 | 2015 | 1312 | 0.060 |
Why?
|
Neoplasms | 1 | 2020 | 2798 | 0.060 |
Why?
|
Texas | 3 | 2023 | 3582 | 0.060 |
Why?
|
Mechanistic Target of Rapamycin Complex 1 | 2 | 2017 | 166 | 0.060 |
Why?
|
Sirolimus | 2 | 2017 | 227 | 0.060 |
Why?
|
Chromosome Aberrations | 2 | 2022 | 620 | 0.060 |
Why?
|
COS Cells | 1 | 2005 | 275 | 0.060 |
Why?
|
Substrate Specificity | 1 | 2005 | 295 | 0.060 |
Why?
|
Catalytic Domain | 1 | 2005 | 159 | 0.060 |
Why?
|
Liquid Biopsy | 1 | 2024 | 14 | 0.060 |
Why?
|
Oncogene Proteins | 1 | 2005 | 143 | 0.060 |
Why?
|
HEK293 Cells | 2 | 2019 | 738 | 0.060 |
Why?
|
Ifosfamide | 1 | 2024 | 31 | 0.060 |
Why?
|
RNA, Messenger | 2 | 2009 | 2810 | 0.060 |
Why?
|
DNA Primers | 1 | 2005 | 657 | 0.060 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2005 | 658 | 0.060 |
Why?
|
Coloring Agents | 1 | 2024 | 75 | 0.060 |
Why?
|
Socioeconomic Factors | 2 | 2017 | 871 | 0.060 |
Why?
|
Registries | 2 | 2025 | 1431 | 0.060 |
Why?
|
Ki-67 Antigen | 1 | 2024 | 114 | 0.050 |
Why?
|
Cloning, Molecular | 1 | 2005 | 897 | 0.050 |
Why?
|
Cells, Cultured | 1 | 2009 | 3041 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 2057 | 0.050 |
Why?
|
Hepatocytes | 1 | 2024 | 210 | 0.050 |
Why?
|
Aged | 5 | 2019 | 19728 | 0.050 |
Why?
|
Morphine | 1 | 2022 | 83 | 0.050 |
Why?
|
Dilatation | 1 | 2002 | 67 | 0.050 |
Why?
|
Myofibroma | 1 | 2021 | 9 | 0.050 |
Why?
|
Bays | 1 | 2021 | 6 | 0.050 |
Why?
|
Length of Stay | 2 | 2021 | 1311 | 0.050 |
Why?
|
Neoadjuvant Therapy | 1 | 2024 | 343 | 0.050 |
Why?
|
Pulmonary Blastoma | 1 | 2021 | 11 | 0.050 |
Why?
|
Pneumoperitoneum, Artificial | 1 | 2001 | 5 | 0.050 |
Why?
|
Pulmonary Gas Exchange | 1 | 2001 | 30 | 0.050 |
Why?
|
Tidal Volume | 1 | 2001 | 39 | 0.050 |
Why?
|
ARNTL Transcription Factors | 1 | 2021 | 39 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2015 | 1428 | 0.050 |
Why?
|
Lipogenesis | 1 | 2021 | 56 | 0.040 |
Why?
|
Benzamides | 1 | 2021 | 110 | 0.040 |
Why?
|
Probability | 1 | 2001 | 318 | 0.040 |
Why?
|
Intersectoral Collaboration | 1 | 2020 | 19 | 0.040 |
Why?
|
Amino Acid Sequence | 1 | 2005 | 2715 | 0.040 |
Why?
|
Middle Aged | 5 | 2019 | 26807 | 0.040 |
Why?
|
Prospective Studies | 2 | 2020 | 6160 | 0.040 |
Why?
|
Endosonography | 1 | 2020 | 78 | 0.040 |
Why?
|
Image-Guided Biopsy | 1 | 2020 | 38 | 0.040 |
Why?
|
Dactinomycin | 1 | 2019 | 66 | 0.040 |
Why?
|
Foot Diseases | 1 | 2019 | 23 | 0.040 |
Why?
|
Genetic Therapy | 1 | 2024 | 688 | 0.040 |
Why?
|
Adenoma, Islet Cell | 1 | 2019 | 8 | 0.040 |
Why?
|
Protein Unfolding | 1 | 2019 | 10 | 0.040 |
Why?
|
Thigh | 1 | 2019 | 51 | 0.040 |
Why?
|
Extremities | 1 | 2019 | 82 | 0.040 |
Why?
|
Zebrafish | 1 | 2021 | 380 | 0.040 |
Why?
|
Remission Induction | 1 | 2019 | 291 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2005 | 1283 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2019 | 101 | 0.040 |
Why?
|
Algorithms | 1 | 2005 | 1632 | 0.040 |
Why?
|
Colonoscopy | 1 | 2020 | 238 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2005 | 1756 | 0.040 |
Why?
|
Nuclear Receptor Coactivator 2 | 1 | 2019 | 201 | 0.040 |
Why?
|
Pediatrics | 2 | 2017 | 1158 | 0.040 |
Why?
|
para-Aminobenzoates | 1 | 2017 | 5 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2021 | 1338 | 0.040 |
Why?
|
Pyrrolidines | 1 | 2017 | 36 | 0.040 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2019 | 214 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2019 | 412 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2017 | 299 | 0.030 |
Why?
|
Chickens | 1 | 2017 | 636 | 0.030 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2017 | 25 | 0.030 |
Why?
|
Infant, Premature, Diseases | 1 | 2019 | 244 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2017 | 73 | 0.030 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2017 | 145 | 0.030 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2016 | 29 | 0.030 |
Why?
|
Social Class | 1 | 2017 | 190 | 0.030 |
Why?
|
Cattle | 1 | 2017 | 567 | 0.030 |
Why?
|
Everolimus | 1 | 2016 | 50 | 0.030 |
Why?
|
Mice, SCID | 1 | 2017 | 586 | 0.030 |
Why?
|
Kidney | 2 | 2015 | 1363 | 0.030 |
Why?
|
Regression Analysis | 1 | 2018 | 780 | 0.030 |
Why?
|
Needs Assessment | 1 | 2017 | 175 | 0.030 |
Why?
|
HSP27 Heat-Shock Proteins | 1 | 2015 | 7 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2016 | 165 | 0.030 |
Why?
|
ErbB Receptors | 1 | 2017 | 283 | 0.030 |
Why?
|
Caspase 3 | 1 | 2015 | 132 | 0.030 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2015 | 63 | 0.030 |
Why?
|
Appendix | 1 | 2015 | 15 | 0.030 |
Why?
|
Aged, 80 and over | 2 | 2017 | 6555 | 0.030 |
Why?
|
Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 29 | 0.030 |
Why?
|
Time Factors | 2 | 2016 | 6318 | 0.030 |
Why?
|
Molecular Chaperones | 1 | 2015 | 167 | 0.030 |
Why?
|
Cause of Death | 1 | 2017 | 472 | 0.030 |
Why?
|
Carcinoma, Papillary | 1 | 2015 | 71 | 0.030 |
Why?
|
Heat-Shock Proteins | 1 | 2015 | 196 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2015 | 586 | 0.030 |
Why?
|
Neural Prostheses | 1 | 2014 | 4 | 0.030 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 23 | 0.030 |
Why?
|
Imidazoles | 1 | 2015 | 205 | 0.030 |
Why?
|
Colony-Forming Units Assay | 1 | 2014 | 70 | 0.030 |
Why?
|
Herpes Simplex Virus Protein Vmw65 | 1 | 2013 | 8 | 0.030 |
Why?
|
Sciatic Nerve | 1 | 2014 | 55 | 0.030 |
Why?
|
Ubiquitin-Specific Peptidase 7 | 1 | 2013 | 17 | 0.030 |
Why?
|
Adenosine Triphosphate | 1 | 2015 | 280 | 0.030 |
Why?
|
Pyridines | 1 | 2015 | 235 | 0.030 |
Why?
|
Sex Distribution | 1 | 2014 | 305 | 0.030 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2014 | 118 | 0.030 |
Why?
|
Fluorouracil | 1 | 2014 | 129 | 0.030 |
Why?
|
Mice, Transgenic | 1 | 2019 | 2412 | 0.030 |
Why?
|
Neoplasms, Adipose Tissue | 1 | 2013 | 8 | 0.030 |
Why?
|
Nerve Regeneration | 1 | 2014 | 74 | 0.030 |
Why?
|
Liposarcoma | 1 | 2013 | 22 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2015 | 670 | 0.030 |
Why?
|
Sex Factors | 1 | 2017 | 1282 | 0.030 |
Why?
|
Disease Management | 1 | 2017 | 531 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2014 | 626 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 560 | 0.020 |
Why?
|
Catheter-Related Infections | 1 | 2014 | 127 | 0.020 |
Why?
|
Genes, myc | 1 | 2012 | 104 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2014 | 772 | 0.020 |
Why?
|
Thoracostomy | 1 | 2011 | 26 | 0.020 |
Why?
|
Colostomy | 1 | 2011 | 26 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 682 | 0.020 |
Why?
|
Preoperative Care | 1 | 2013 | 353 | 0.020 |
Why?
|
Anal Canal | 1 | 2011 | 82 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2012 | 1018 | 0.020 |
Why?
|
Motor Activity | 1 | 2014 | 520 | 0.020 |
Why?
|
Practice Patterns, Physicians' | 1 | 2016 | 731 | 0.020 |
Why?
|
Spine | 1 | 2011 | 142 | 0.020 |
Why?
|
Limb Deformities, Congenital | 1 | 2011 | 105 | 0.020 |
Why?
|
Risk | 1 | 2012 | 759 | 0.020 |
Why?
|
Aurora Kinases | 1 | 2009 | 32 | 0.020 |
Why?
|
Serine | 1 | 2010 | 175 | 0.020 |
Why?
|
Fibroblasts | 1 | 2014 | 887 | 0.020 |
Why?
|
Trachea | 1 | 2011 | 203 | 0.020 |
Why?
|
Benzazepines | 1 | 2009 | 64 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2014 | 909 | 0.020 |
Why?
|
Logistic Models | 1 | 2014 | 1808 | 0.020 |
Why?
|
Postoperative Care | 1 | 2011 | 301 | 0.020 |
Why?
|
Radiography | 1 | 2011 | 809 | 0.020 |
Why?
|
Hospitals, Pediatric | 1 | 2013 | 765 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2014 | 2901 | 0.020 |
Why?
|
Rats | 1 | 2014 | 3725 | 0.020 |
Why?
|
Genetic Testing | 1 | 2013 | 1013 | 0.020 |
Why?
|
Risk Factors | 1 | 2016 | 10287 | 0.010 |
Why?
|